WHO concerned about transmission of monkeypox in South America.
The World Health Organization said on Thursday it had seen a 21% reduction in new cases of monkeypox reported globally last week, with the outbreak beginning to slow in Europe.
But the WHO is far from happy about the situation, as it notes an intense transmission of the epidemic on the American continent.
At the start of the outbreak, most reported cases were in Europe, with a smaller portion in the Americas. This situation has now reversed, with less than 40% of cases reported in Europe and 60% in the Americas, WHO Director General Tedros Adhanom Ghebreyesus said at a press conference. p>
In Latin America in particular, insufficient awareness or insufficient public health measures, combined with lack of access to vaccines, are fueling the epidemic, he said. -he raised.
Previously restricted to West and Central Africa, monkeypox has spread since May to other parts of the world, including Europe and the United States, with a total of 44,464 cases recorded as of August 24 worldwide, including 13 deaths, according to the latest online report from the WHO.
After four consecutive weeks of increase , the number of reported cases worldwide decreased by 21% during the week of August 15-21, compared to the previous week, according to the WHO's weekly report on monkeypox.
According to this report, in the past seven days, two countries have reported their first cases: Iran and Indonesia.
There are signs that indicate that the epidemic is slowing in Europe, where a combination of effective public health measures, behavioral changes and vaccination are helping to prevent transmission, Dr Tedros explained.
WHO triggered the highest level of alert, the Public Health Emergency of International Concern, on July 24 to step up the fight against the disease.
Bavarian Nordic, the Danish laboratory producing the only licensed monkeypox vaccine, announced on Wednesday an agreement with the WHO to facilitate its distribution in countries in Latin America and the Caribbean.
We thank Bavarian Nordic for this agreement, and we hope it will help bring the outbreak under control in the region, Dr Tedros said on Thursday.
WHO continues to encourage all countries to set up vaccine efficacy studies to ensure data collection while improving access to vaccines. doses, he said.
Marketed by Bavarian Nordic as Jynneos in North America and Imvanex in Europe, it is a vaccine against smallpox human, a deadly disease eradicated in 1980, which is currently used against monkeypox.